Drug Manufacturer Stocks: Teva Pharmaceutical Industries (NYSE:TEVA), Prana Biotechnology (NASDAQ:PRAN), Amarin Corporation (NASDAQ:AMRN), Depomed Inc (NASDAQ:DEPO)

FB Nasdaq FB Facebook

National Alliance Securities assumed coverage on shares of Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) in a research note issued to investors on Monday, Analyst Ratings Netreports. The firm issued a buy rating and a $64.22 price target on the stock. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -1.18% in last session and finished the day at $50.90. Traded volume was 500.00million shares in the last session and the average volume of the stock remained 7.39million shares. The beta of the stock remained 0.59.

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) announced that its Phase II trials for the development of a therapy for Alzheimer’s condition failed. Alzheimer’s is another mental illness which shares some similarities with schizophrenia. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) rose 1.83 percent to $2.23 Tuesday on volume of 1.70million shares. The intra-day range of the stock was $2.13 to $2.27. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has a market capitalization of $92.88million.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) has received a consensus recommendation of “Hold” from the fourteen brokerages that are covering the stock, American Banking News reports. Ten research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s stock on Apr 08, 2014 reported a decrease of -2.76% to the closing price of $1.76. Its fifty two weeks range is $1.36 -$7.98. The total market capitalization recorded $303.49million. The overall volume in the last trading session was 2.71million shares. In its share capital, AMRN has 172.43million outstanding shares.

Investment analysts at Roth Capital upped their price target on shares of Depomed Inc (NASDAQ:DEPO) from $12.50 to $14.00 in a note issued to investors on Friday, American Banking & Market News reports. Roth Capital’s price target would suggest a potential upside of 3.70% from the stock’s previous close. Separately, analysts at EVA Dimensions upgraded shares of Depomed Inc (NASDAQ:DEPO) from an “underweight” rating to a “hold” rating in a research note on Thursday, March 13th. On Tuesday, shares of Depomed Inc (NASDAQ:DEPO) advanced 2.22% to close the day at $13.80. Company return on investment (ROI) is 32.30% and its monthly performance is recorded as 1.85%. Depomed Inc (NASDAQ:DEPO) quarterly revenue growth is 26.03%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone